ES2536558T3 - Sal citrato de 11-(2-pirrolidin-1-il-etoxi)-14,19-dioxa-5,7,26-triaza-tetraciclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-deceno - Google Patents

Sal citrato de 11-(2-pirrolidin-1-il-etoxi)-14,19-dioxa-5,7,26-triaza-tetraciclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-deceno Download PDF

Info

Publication number
ES2536558T3
ES2536558T3 ES09788621.2T ES09788621T ES2536558T3 ES 2536558 T3 ES2536558 T3 ES 2536558T3 ES 09788621 T ES09788621 T ES 09788621T ES 2536558 T3 ES2536558 T3 ES 2536558T3
Authority
ES
Spain
Prior art keywords
tetracycle
heptacosa
triaza
dioxa
decene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09788621.2T
Other languages
English (en)
Inventor
Brian Dymock
Cheng Hsia Angeline Lee
Anthony Deodaunia William
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CTI Biopharma Corp
Original Assignee
CTI Biopharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CTI Biopharma Corp filed Critical CTI Biopharma Corp
Application granted granted Critical
Publication of ES2536558T3 publication Critical patent/ES2536558T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/22—Tricarboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D201/00—Preparation, separation, purification or stabilisation of unsubstituted lactams
    • C07D201/02—Preparation of lactams
    • C07D201/10—Preparation of lactams from cycloaliphatic compounds by simultaneous nitrosylation and rearrangement
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)

Abstract

Una sal citrato de 11-(2-pirrolidin-1-il-etoxi)-14,19-dioxa-5,7,26-triaza-tetraciclo[19.3.1.1(2,6).1(8,12)]heptacosa- 1(25),2(26),3,5,8,10,12(27),16,21,23-deceno.
ES09788621.2T 2008-12-11 2009-12-09 Sal citrato de 11-(2-pirrolidin-1-il-etoxi)-14,19-dioxa-5,7,26-triaza-tetraciclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-deceno Active ES2536558T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US121668P 1999-02-25
US12166808P 2008-12-11 2008-12-11
PCT/SG2009/000473 WO2010068181A1 (en) 2008-12-11 2009-12-09 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6)1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27)j16,21,23-decaene citrate salt

Publications (1)

Publication Number Publication Date
ES2536558T3 true ES2536558T3 (es) 2015-05-26

Family

ID=41666397

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09788621.2T Active ES2536558T3 (es) 2008-12-11 2009-12-09 Sal citrato de 11-(2-pirrolidin-1-il-etoxi)-14,19-dioxa-5,7,26-triaza-tetraciclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-deceno

Country Status (23)

Country Link
US (2) US8980873B2 (es)
EP (1) EP2376499B1 (es)
JP (1) JP5669748B2 (es)
KR (1) KR101729918B1 (es)
CN (1) CN102282148B (es)
AR (2) AR074724A1 (es)
AU (1) AU2009325147B2 (es)
BR (1) BRPI0922736B1 (es)
CA (1) CA2746058C (es)
DK (1) DK2376499T3 (es)
ES (1) ES2536558T3 (es)
HR (1) HRP20150428T1 (es)
IL (3) IL213418A0 (es)
MX (1) MX2011006206A (es)
MY (1) MY160005A (es)
NZ (1) NZ593223A (es)
PL (1) PL2376499T3 (es)
PT (1) PT2376499E (es)
RU (1) RU2527970C2 (es)
SG (1) SG171907A1 (es)
TW (1) TWI449705B (es)
WO (1) WO2010068181A1 (es)
ZA (1) ZA201104032B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2376500T3 (pl) * 2008-12-11 2015-07-31 Cti Biopharma Corp Sól maleinianowa 11-(2-pirrolidyn-1-yloetoksy)-14,19-dioksa-5,7,26 triazatetracyklo[19.3.1.1(2,6).1(8,12)]heptakosa-1(25),2(26),3,5,8,10,12(27),16,21,23-dekaenu
CN102282148B (zh) 2008-12-11 2014-12-24 Cti生物医药有限公司 11-(2-吡咯烷-1-基-乙氧基)-14,19-二氧杂-5,7,26-三氮杂-四环[19.3.1.1(2,6).1(8,12)]二十七碳-1(25),2(26),3,5,8,10,12(27),16,21,23-十烯柠檬酸盐
US9090623B2 (en) 2012-04-13 2015-07-28 Lianyungang Jinkang Hexin Pharmaceutical Co., Ltd. Compound JK12A and preparation thereof
CN105061467B (zh) * 2015-08-28 2017-08-25 苏州立新制药有限公司 一种帕克替尼的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5728536A (en) 1993-07-29 1998-03-17 St. Jude Children's Research Hospital Jak kinases and regulation of Cytokine signal transduction
US6136595A (en) 1993-07-29 2000-10-24 St. Jude Children's Research Hospital Jak kinases and regulations of cytokine signal transduction
CA2446988A1 (en) * 2001-05-14 2002-11-21 Pfizer Products Inc. The citrate salt of 5, 8, 14-triazatetracyclo(10.3.1.02,11.04.9)-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof
US6433018B1 (en) 2001-08-31 2002-08-13 The Research Foundation Of State University Of New York Method for reducing hypertrophy and ischemia
IL161326A0 (en) * 2001-11-29 2004-09-27 Pfizer Prod Inc Succinic acid salts of 5,8,14-triazatetracyclo'10.3.1.0<2,11>.0<4,9>-hexadeca-2 (11),3,5,7,9-pentaene and pharmaceutical compositions thereof
CN101360751B (zh) 2005-11-16 2011-09-14 S*Bio私人有限公司 氧连接的嘧啶衍生物
CN102282148B (zh) 2008-12-11 2014-12-24 Cti生物医药有限公司 11-(2-吡咯烷-1-基-乙氧基)-14,19-二氧杂-5,7,26-三氮杂-四环[19.3.1.1(2,6).1(8,12)]二十七碳-1(25),2(26),3,5,8,10,12(27),16,21,23-十烯柠檬酸盐

Also Published As

Publication number Publication date
RU2011126173A (ru) 2013-01-20
WO2010068181A1 (en) 2010-06-17
JP5669748B2 (ja) 2015-02-12
MY160005A (en) 2017-02-15
US8980873B2 (en) 2015-03-17
HRP20150428T1 (xx) 2015-06-19
CN102282148B (zh) 2014-12-24
DK2376499T3 (en) 2015-05-04
US20150322084A1 (en) 2015-11-12
IL289379A (en) 2022-02-01
RU2527970C2 (ru) 2014-09-10
IL250310A0 (en) 2017-03-30
EP2376499B1 (en) 2015-02-25
AU2009325147B2 (en) 2014-08-14
NZ593223A (en) 2013-08-30
PT2376499E (pt) 2015-06-03
JP2012511571A (ja) 2012-05-24
TWI449705B (zh) 2014-08-21
PL2376499T3 (pl) 2015-07-31
CA2746058C (en) 2016-05-17
TW201028426A (en) 2010-08-01
AR114133A2 (es) 2020-07-22
BRPI0922736A2 (pt) 2017-10-31
KR20110106344A (ko) 2011-09-28
CN102282148A (zh) 2011-12-14
MX2011006206A (es) 2011-07-20
SG171907A1 (en) 2011-07-28
WO2010068181A8 (en) 2011-08-18
AR074724A1 (es) 2011-02-09
HK1161877A1 (en) 2012-08-10
KR101729918B1 (ko) 2017-04-25
IL213418A0 (en) 2011-07-31
CA2746058A1 (en) 2010-06-17
US20110294831A1 (en) 2011-12-01
US9624242B2 (en) 2017-04-18
BRPI0922736A8 (pt) 2021-11-09
BRPI0922736B1 (pt) 2022-02-22
ZA201104032B (en) 2012-08-29
EP2376499A1 (en) 2011-10-19
AU2009325147A1 (en) 2011-06-23

Similar Documents

Publication Publication Date Title
NL301021I1 (nl) talazoparib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout.
CR20110432A (es) Pirimidinas fusionadas
CR11512A (es) Compuestos insecticidas
EA200801959A1 (ru) Высокоразветвленный полипропилен
MX2010009222A (es) Soluciones farmaceuticas, proceso de preparacion y usos terapeuticos.
CY1119121T1 (el) Αμορφο αλας ενος μακροκυκλικου αναστολεα του hcv
TW200740776A (en) N-phenylbenzotriazolyl c-kit inhibitors
EA201000883A1 (ru) Производные индолинона и способ их получения
BRPI0923351A2 (pt) &#34;implante dentário em múltiplas partes.&#34;
IL289379A (en) Citrate salt of 11-(2-pyrrolidin-1-yl-ethoxy)-19,14-dioxa-26,7,5-triaza-tetracyclo[1.1.3.19(6,2)1(12,8)]hepatacosa- 1(25),2(26),12,10,8,5,3(27)j23,21,16–Decan
WO2011033062A3 (en) Disulfo-type fluorescent whitening agents
EA200900780A1 (ru) Аналоги эпотилона, модифицированные в положениях c12-c13, как противораковые лекарственные средства
DOP2011000154A (es) 3-aminociclopentancarboxamidas
HRP20181437T1 (hr) Postupak proizvodnje (3s,3s&#39;) 4,4&#39; disulfanedilbis (3-aminobutan-1-sulfonske kiseline)
DOP2006000233A (es) Inhibidores de cinasa
BR112012000750A2 (pt) &#34;sal citrato de 9e-15-(2-pirrolidin-1-il-etóxi)-7,12,25-trioxa-19,21,24-triaza-tetraciclo[18.3.1.1(2,5).1(14.18)]hexacosa-1(24),2,4,9,14,16,18(26),20,22-nonaeno&#34;
EA201190256A1 (ru) Способ снижения уровня убиквитинилированных белков
EA200900816A1 (ru) Антибактериальные соединения и способы их получения
PT2376500E (pt) Sal maleato de 11-(2-pirrolidin-1-il-etoxi)-14,19-dioxa- 5,7,26-triaza-tetraciclo[19.3.1.1(2,6).1(8,12)]heptacosa- 1(25),2(26),3,5,8,10,12(27),16,21,23-decaeno
EA201300719A3 (ru) Способ ферментативного синтеза (7s)-1-(3,4-диметоксибицикло[4.2.0]окта-1,3,5-триен-7-ил) n-метилметанамина, и применение в синтезе ивабрадина и его солей
EA200970692A1 (ru) Способы улучшения стабильности стероидных производных
ITMO20050182A1 (it) Ago per biopsia dei tessuti molli.
IL194337A0 (en) Method for preparing lysobactin derivatives
DE602006014001D1 (de) Herstellung von 2-aminothiazol-5-carbonsäurederivaten
EA201170509A1 (ru) Селективный модулятор рецепторов эстрогена